Expanding Nora Pharma's footprint in the Canadian generic drug market by launching at least 12 additional generic products throughout 2026, targeting high-demand therapeutic areas such as oncology, cardiovascular health, central nervous system disorders, and antimicrobials.

Expected impact: Provides foundational, steady-state cash flow to support the company's proprietary drug development programs and move the company closer to near-term profitability.

Implementation of cost-reduction initiatives designed to lower general and administrative expenses and better align the corporate cost structure with near-term profitability goals.

Expected impact: Expected to reduce annual operating expenses by approximately $2 million to $3 million in 2026.

Advancing proprietary drug development programs, specifically the K1.1 mRNA therapy targeting liver cancer and the newly patented PLpro protease inhibitor platform for coronavirus infections.

Expected impact: Transitions the company from a pure generics distributor to a high-upside clinical-stage innovator, creating long-term valuation upside.